Technical Analysis for AMAG - AMAG Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 17.25 -2.16% -0.38
AMAG closed down 2.16 percent on Wednesday, December 12, 2018, on 88 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AMAG trend table...

Date Alert Name Type % Chg
Dec 12 20 DMA Resistance Bearish 0.00%
Dec 12 Oversold Stochastic Weakness 0.00%
Dec 11 20 DMA Resistance Bearish -2.16%
Dec 11 Stochastic Reached Oversold Weakness -2.16%
Dec 11 BB Squeeze Ended Range Expansion -2.16%
Dec 11 Oversold Stochastic Weakness -2.16%
Dec 10 Bollinger Band Squeeze Range Contraction -3.25%
Dec 7 Fell Below 20 DMA Bearish -1.43%
Dec 7 180 Bearish Setup Bearish Swing Setup -1.43%
Dec 7 Bollinger Band Squeeze Range Contraction -1.43%

Older signals for AMAG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company's principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company also markets Feraheme in Canada, the European Union, and Switzerland. In addition, its development projects comprise Feraheme for patients with IDA regardless of the underlying cause, which has completed Phase III clinical program. The company sells Feraheme primarily to authorized wholesalers and specialty distributors. AMAG Pharmaceuticals, Inc. has a license, development, and commercialization agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Feraheme/Rienso as a therapeutic agent in Europe, certain Asia-Pacific countries, the Commonwealth of Independent States, Canada, India, and Turkey; and collaboration and exclusive license agreement with 3SBio for the development and commercialization of Feraheme as a therapeutic agent in China for an initial indication for the treatment of IDA in patients with CKD and an option to expand into additional therapeutic indications. The company was founded in 1981 and is headquartered in Lexington, Massachusetts.
Is AMAG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.1
52 Week Low 11.95
Average Volume 768,099
200-Day Moving Average 21.5066
50-Day Moving Average 19.8294
20-Day Moving Average 17.8775
10-Day Moving Average 17.885
Average True Range 0.9648
ADX 20.7
+DI 16.8856
-DI 18.5212
Chandelier Exit (Long, 3 ATRs ) 16.5456
Chandelier Exit (Short, 3 ATRs ) 19.4944
Upper Bollinger Band 18.7029
Lower Bollinger Band 17.0521
Percent B (%b) 0.12
BandWidth 9.233953
MACD Line -0.5432
MACD Signal Line -0.6161
MACD Histogram 0.0729
Fundamentals Value
Market Cap 608.72 Million
Num Shares 35.3 Million
EPS -1.30
Price-to-Earnings (P/E) Ratio -13.27
Price-to-Sales 0.90
Price-to-Book 0.57
PEG Ratio 0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.56
Resistance 3 (R3) 18.68 18.38 18.34
Resistance 2 (R2) 18.38 18.04 18.31 18.26
Resistance 1 (R1) 17.81 17.84 17.66 17.69 18.19
Pivot Point 17.51 17.51 17.43 17.44 17.51
Support 1 (S1) 16.94 17.17 16.79 16.82 16.31
Support 2 (S2) 16.64 16.97 16.57 16.24
Support 3 (S3) 16.07 16.64 16.16
Support 4 (S4) 15.95